Screener
DaVita DVA U.S.Dialysis And Related Lab Services — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by DaVita in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: DaVita’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 5:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000927066-26-000062
| Line item | Three months ended March 31, 2026 / U.S. dialysis | Three months ended March 31, 2026 / Other — Ancillary services | Three months ended March 31, 2026 / Consolidated | Three months ended March 31, 2025 / U.S. dialysis | Three months ended March 31, 2025 / Other — Ancillary services | Three months ended March 31, 2025 / Consolidated |
|---|---|---|---|---|---|---|
| Commercial | 954,243 | 109,664 | 1,063,907 | 924,888 | 87,819 | 1,012,707 |
| Other revenues: | ||||||
| Medicare and Medicare Advantage | 108,506 | 108,506 | 98,954 | 98,954 | ||
| Medicaid and Managed Medicaid | — | — | 2 | 2 | ||
| Commercial | 3,648 | 3,648 | 2,701 | 2,701 | ||
| Other(1) | 6,275 | 27,610 | 33,885 | 6,008 | 15,599 | 21,607 |
| Eliminations of intersegment revenues | (20,472) | (3,288) | (23,760) | (11,734) | (2,728) | (14,462) |
| Total | $2,921,229 | $494,319 | $3,415,548 | $2,811,435 | $412,094 | $3,223,529 |
Item 1. Condensed Consolidated Financial Statements:
FAQ
- What is DaVita's u.s.dialysis and related lab services — revenue?
- DaVita (DVA) reported u.s.dialysis and related lab services — revenue of $2.92B in Q1 2026.
- How has DaVita's u.s.dialysis and related lab services — revenue changed year-over-year?
- DaVita's u.s.dialysis and related lab services — revenue increased by 3.9% year-over-year, from $2.81B to $2.92B.
- What does u.s.dialysis and related lab services — revenue mean?
- This metric represents the total revenue generated from dialysis treatments and associated laboratory services provided within the United States. It serves as the primary indicator of the company's core business performance and market penetration in the domestic renal care sector. Revenue is heavily influenced by patient volume, treatment frequency, and the mix of government versus commercial reimbursement rates.
Ask your AI about DaVita's u.s.dialysis and related lab services — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude